TRATAMIENTO FARMACOLOGICO DEL DOLOR NEUROPATICO
Columnista Experta de SIIC Gary McCleane
en colaboración con
Fecha de aprobación: 26 de abril, 2005
Primera edición en siicsalud:
3 de noviembre, 2005
Sección Artículos originales,
subsección
Expertos de Iberoamérica,
página
/des/expertocompleto.php/73398
Especialidad principal:
Neurología
Especialidades relacionadas:
Anestesiología,Farmacología,Medicina Farmacéutica,Medicina Interna,
McCleane GJ. Cholecystokinin antagonists: a new way to improve analgesia from old analgesics: a review, Current Pharmaceutical Design 10:302-314, 2004
McCleane GJ. Pharmaceutical strategies in relieving neuropathic pain: a review, Expert Opinion in Phramacotherapy 5:1299-1312, 2004
McCleane GJ. A randomized double blind placebo controlled study of the cholecystokinin 2 antagonist L365,260 as an adjunct to strong opioids in chronic human neuropathic pain, Neuroscience Letters 338:151-154, 2003
McCleane GJ, Suzuki R, Dickenson A.. Does a single intravenous injection of the 5HT3 receptor antagonist ondansetron have an analgesic effect in neuropathic pain: A double blind placebo controlled crossover study, Anesthetsia & Analgesia 97:1474-1478, 2003
McCleane GJ. Pharmacological management of neuropathic pain: a review, CNS Drugs 17:1031-1043, 2003
McCleane GJ. The analgesic efficacy of topical capsaicin is enhanced by glyceryltrintrate in painful osteoarthritis: a randomized, double blind placebo controlled study, European Journal of Pain 4:355-360, 2000
Gary McCleane
